Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.65 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | CRHBP | P24387 | 1/20 | 0.54 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.54 |
| ▸ | CDK1 | P06493 | 1/20 | 0.51 |
| ▸ | CDK2 | P24941 | 1/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17626748 | 0.83 | HRH3 (0.71) | HRH3HRH4CDK2OGAROCK1 | |
| SCHEMBL14880196 | 0.83 | HRH3 (0.71) | HRH3HRH4CRHBPCRHR2USP2 | |
| SCHEMBL10932400 | 0.81 | HRH3 (0.69) | HRH3HRH4CRHBPCRHR2USP2 | |
| Bromide SCHEMBL20445910 | 0.81 | HRH3 (0.69) | HRH3HRH4CRHBPCRHR2USP2 | |
| SCHEMBL17626780 | 0.81 | HRH3 (0.81) | HRH3HRH4CYP1A2CYP2D6MEN1 | |
| SCHEMBL5457199 | 0.80 | PIK3CA (0.55) | HRH4CYP1A2CDK2PIK3CAPIK3CD | |
| SCHEMBL2167882 | 0.79 | HRH3 (1.00) | HRH3HRH4CYP1A2USP2ALDH1A1 | |
| SCHEMBL13018736 | 0.79 | HRH3 (0.70) | HRH3HRH4CDK2OGAROCK1 | |
| SCHEMBL2166051 | 0.79 | HRH4 (1.00) | HRH3HRH4CYP1A2CYP2D6USP2 | |
| SCHEMBL21914804 | 0.79 | PIK3CA (0.50) | CYP1A2PIK3CAPIK3CDMEN1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | INITIAL THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2024226875-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS | INITIAL THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| CN-112457260-B | N-heterocyclic aryl quinazoline-4-amine compound and preparation method thereof | 江苏食品药品职业技术学院 | 2023-01-17 | — | — | CN | disclosed |
| CN-114890955-A | Preparation process of N-substituted morpholine organic compound | 江西瑞威尔生物科技有限公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-114835683-A | Quinazoline-4, 6-diamine compound containing morpholinyl aromatic heterocycle and preparation method thereof | 江苏食品药品职业技术学院 | 2022-08-02 | — | — | CN | disclosed |
| CN-108135175-B | Bicyclic compounds and their use for inhibition of SUV39H2 | 肿瘤疗法科学股份有限公司 | 2021-04-06 | — | — | CN | disclosed |
| EP-3355699-B1 | BICYCLIC COMPOUND AND USE THEREOF FOR INHIBITING SUV39H2 | ONCOTHERAPY SCIENCE INC (JP) | 2021-03-31 | — | — | EP | disclosed |
| CN-112457260-A | N-heterocyclic aryl quinazoline-4-amine compound and preparation method thereof | 江苏食品药品职业技术学院 | 2021-03-09 | — | — | CN | disclosed |
| US-20180273529-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR INHIBITING SUV39H2 | ONCOTHERAPY SCIENCE, INC. (JP) | 2018-09-27 | — | — | US | disclosed |
| US-9801961-B2 | 2-phenylimidazo[1,2-a]pyrimidines as imaging agents | HOFFMANN-LA ROCHE INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-20130079342-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. | 2013-03-28 | — | — | US | disclosed |
| US-20130079342-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. | 2013-03-28 | — | — | US | disclosed |
| US-20130079342-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. | 2013-03-28 | — | — | US | disclosed |
| CN-102317282-A | Hetero ring derivative | ASTELLAS PHARMA INC | 2012-01-11 | — | — | CN | disclosed |
| WO-2012003264-A1 | NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS AS PIK3 -DELTA INHIBITORS | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012003264-A1 | NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS AS PIK3 -DELTA INHIBITORS | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2011136483-A1 | NOVEL COMPOUNDS FOR ORGANIC ELECTRONIC MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME | ROHM AND HAAS ELECTRONIC MATERIALS KOREA LTD. (KR) | 2011-11-03 | — | — | WO | disclosed |
| WO-2008132502-A1 | PYRAZOLYL-AMINO-SUBSTITUTED PYRIMIDINES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2003024448-A2 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2003-03-27 | — | — | WO | disclosed |
| EP-0107027-B1 | HAIR DYEING COMPOSITIONS | Henkel Kommanditgesellschaft auf Aktien (DE) | 1985-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180273529-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR INHIBITING SUV39H2 | SUV39H2, SUV39H1, EZH1 | HRH3 199/4885HRH4 511/4885CYP1A2 3455/4885 |
| US-20130079342-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | HRH3 551/4885HRH4 886/4885CYP1A2 1609/4885 |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | MYCBP, MYC, MYCBP2 | HRH3 3980/4885HRH4 4286/4885CYP1A2 4149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.